Boehringer Ingelheim's Ofev nabs FDA nod for expanded use in rare lung disease

Boehringer Ingelheim's Ofev can now treat between 18% and 32% of patients with an interstitial lung disease. (Boehringer)

Boehringer Ingelheim cast a wide net with its clinical program for pulmonary fibrosis med Ofev, hoping to carve out a sales niche in a huge range of ultrarare lung diseases. Already sporting an FDA nod in one subclass, Ofev can now target an even larger patient pool with its newest approval.

The FDA on Monday approved Ofev to treat patients with range of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype, Boehringer said in a release. 

Ofev's newest approval covers between 18% and 32% of total patients with an ILD, a category that includes around 200 diseases that can lead to irreversible scarring of lung tissue, Boehringer said.


De-risking the Development of Biotherapeutics Using Early Stage In Vitro Expression and Genetic Characterisation Tools

Wednesday, July 8, 2020 | 11am EST / 8am PST

This webinar will describe strategies to mitigate risks, reduce attrition and help improve the quality and safety of your drug candidate.

Ofev already sports FDA approvals to treat pulmonary fibrosis and systemic sclerosis-associated ILD (SSc-ILD), another subclass of ILDs that is believed to affect about 50,000 Americans each year. 

RELATED: Boehringer Ingelheim's Ofev cuts rate of decline by 57% in range of rare lung diseases

The FDA based its review on data from Boehringer's phase 3 Inbuild study, which showed Ofev significantly slowed the rate of lung function decline in patients with a range of progressive, non-IPF ILDs by 57% over placebo after 52 weeks.

Inbuild on the whole studied Ofev in a wide range of ILDs, including those with a progressive phenotype and SSc-ILD, the drugmaker said, an indication where Ofev notched an FDA nod in September. That approval––the first of its kind––followed a phase 3 clinical trial, dubbed Senscis, in which Ofev beat out placebo in terms of slowing the decline of forced vital capacity—a measure of lung function—in 576 patients treated for a minimum of 52 weeks and maximum of 100 weeks. 

Ofev received its initial approval in idiopathic pulmonary fibrosis back in 2014.

Suggested Articles

Johnson & Johnson has expanded its COVID-19 vaccine production pact with CDMO Catalent to include work at the manufacturer's Anagni, Italy site.

German vaccine maker CureVac scored an $85 million EU loan to expand manufacturing for its mRNA-based COVID-19 vaccine hopeful.

Learn how drug substance and drug product early development strategies are important for optimization and long-term success.